# SNCAIP

## Overview
The SNCAIP gene encodes the synphilin-1 protein, which is primarily involved in protein-protein interactions within neuronal cells. Synphilin-1 is characterized by its ankyrin repeat domains and coiled-coil regions, which facilitate its interaction with α-synuclein, a protein implicated in the pathogenesis of Parkinson's disease (Engelender1999Synphilin1). This interaction is crucial for various cellular processes, including synaptic vesicle trafficking and protein degradation pathways, and is associated with the formation of Lewy body-like inclusions, a hallmark of neurodegenerative diseases (Maraganore2003Case‐control). The protein is ubiquitinated by parkin, an E3 ubiquitin ligase, which is significant for its role in proteasomal degradation pathways (Hernandez2020ProteinProtein). While SNCAIP has been implicated in neurodegenerative diseases such as Parkinson's disease, its exact role and the impact of its genetic variants remain areas of active research (Gialluisi2021Identification).

## Structure
The SNCAIP gene encodes the synphilin-1 protein, which is involved in protein-protein interactions, particularly with α-synuclein. Synphilin-1 is characterized by its ankyrin repeat domains and coiled-coil regions, which facilitate these interactions (Maraganore2003Case‐control). The primary structure of synphilin-1 consists of amino acid sequences that are highly conserved between mouse and human, especially in regions containing ankyrin-like motifs and coiled-coil domains (Maraganore2003Case‐control).

The secondary structure of synphilin-1 includes these ankyrin repeat domains, which are known for forming helix-loop-helix structures, and coiled-coil regions that typically form alpha-helices. These structural features are crucial for the protein's ability to interact with other proteins, such as α-synuclein, in neurons (Maraganore2003Case‐control).

Post-translational modifications of synphilin-1 include ubiquitination, which is mediated by the parkin protein. This modification is significant for the protein's role in the formation of Lewy body-like inclusions, a hallmark of Parkinson's disease (Maraganore2003Case‐control). The presence of synphilin-1 in Lewy bodies suggests its involvement in neurodegenerative processes (Maraganore2003Case‐control).

## Function
SNCAIP, also known as synphilin-1, is a protein that interacts specifically with alpha-synuclein (aSyn) in neurons. This interaction is crucial for several cellular processes, including the regulation of synaptic vesicle trafficking and protein degradation pathways. SNCAIP is primarily active in the cytoplasm and is associated with cellular structures such as the endoplasmic reticulum and Golgi apparatus (Maraganore2003Case‐control). In healthy human cells, SNCAIP may reversibly link alpha-synuclein to synaptic vesicles, with alpha-synuclein negatively regulating this association (Maraganore2003Case‐control).

SNCAIP is involved in the proteasomal degradation pathway, which is essential for maintaining protein homeostasis by degrading misfolded or damaged proteins. It interacts with proteins involved in proteasomal and autophagy pathways, such as the 26S proteasome and PSMC3, suggesting a role in influencing alpha-synuclein aggregation and degradation (Hernandez2020ProteinProtein). The protein parkin ubiquitinates SNCAIP, and co-expression of PARK2, SNCAIP, and alpha-synuclein in cells results in Lewy body-like inclusions, indicating its involvement in protein aggregation processes (Maraganore2003Case‐control). These interactions are crucial for maintaining neuronal health and function, potentially impacting disease progression when dysregulated.

## Clinical Significance
Mutations and alterations in the SNCAIP gene, which encodes synphilin-1, have been implicated in several neurodegenerative diseases, particularly Parkinson's disease (PD). Synphilin-1 interacts with α-synuclein, a protein central to PD pathology, and promotes the formation of cytosolic inclusions similar to Lewy bodies, which are characteristic of PD (Engelender1999Synphilin1). Although SNCAIP is a plausible candidate gene for PD due to its interaction with α-synuclein and presence in Lewy bodies, studies have not consistently found significant associations between SNCAIP variants and PD (Maraganore2003Case‐control). 

Research has identified rare SNCAIP variants in early-onset dementia patients, suggesting a potential role in neurodegeneration, although the association with PD remains uncertain (Luukkainen2020Mutation). Additionally, SNCAIP has been identified as a candidate gene in genetic studies of PD, with rare variants potentially contributing to disease risk (Gialluisi2021Identification). Beyond neurodegenerative diseases, SNCAIP mutations have been observed in metastatic clear cell renal cell carcinoma, indicating a possible role in cancer progression, though the clinical significance is not fully understood (Meng2020Genomic).

## Interactions
SNCAIP, also known as synphilin-1, is a protein that interacts with α-synuclein, a key player in the pathogenesis of Parkinson's disease. This interaction is significant as it promotes the formation of cytosolic inclusions resembling Lewy bodies, which are characteristic of the disease (Engelender1999Synphilin1). The interaction between synphilin-1 and α-synuclein is particularly strong with the A53T mutant of α-synuclein, suggesting a potential role in disease pathogenesis (Engelender1999Synphilin1).

Synphilin-1 contains several protein-protein interaction domains, such as ankyrin-like repeats and a coiled-coil domain, which may facilitate its role as an adaptor molecule, anchoring α-synuclein to intracellular proteins involved in vesicle transport and cytoskeletal function (Engelender1999Synphilin1). It is also ubiquitinated by parkin, an E3 ubiquitin ligase encoded by the PARK2 gene, which is associated with early-onset familial parkinsonism. This ubiquitination process is crucial for the formation of Lewy body-like inclusions when SNCAIP, SNCA, and PARK2 are co-expressed in cells (Maraganore2003Case‐control).

SNCAIP is involved in the proteasomal degradation pathway, which is responsible for the degradation of α-synuclein, potentially influencing its aggregation and degradation (Hernandez2020ProteinProtein).


## References


[1. (Engelender1999Synphilin1) Simone Engelender, Zachary Kaminsky, Xin Guo, Alan H. Sharp, Ravi K. Amaravi, John J. Kleiderlein, Russell L. Margolis, Juan C. Troncoso, Anthony A. Lanahan, Paul F. Worley, Valina L. Dawson, Ted M. Dawson, and Christopher A. Ross. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics, 22(1):110–114, May 1999. URL: http://dx.doi.org/10.1038/8820, doi:10.1038/8820. This article has 385 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/8820)

[2. (Hernandez2020ProteinProtein) Sarah M. Hernandez, Elena B. Tikhonova, and Andrey L. Karamyshev. Protein-protein interactions in alpha-synuclein biogenesis: new potential targets in parkinson’s disease. Frontiers in Aging Neuroscience, March 2020. URL: http://dx.doi.org/10.3389/fnagi.2020.00072, doi:10.3389/fnagi.2020.00072. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnagi.2020.00072)

[3. (Luukkainen2020Mutation) Laura Luukkainen, Samuli Huttula, Henri Väyrynen, Seppo Helisalmi, Laura Kytövuori, Annakaisa Haapasalo, Mikko Hiltunen, Anne M. Remes, and Johanna Krüger. Mutation analysis of the genes associated with parkinson’s disease in a finnish cohort of early-onset dementia. Journal of Alzheimer’s Disease, 76(3):955–965, August 2020. URL: http://dx.doi.org/10.3233/jad-200069, doi:10.3233/jad-200069. This article has 0 citations.](https://doi.org/10.3233/jad-200069)

[4. (Gialluisi2021Identification) Alessandro Gialluisi, Mafalda Giovanna Reccia, Nicola Modugno, Teresa Nutile, Alessia Lombardi, Luca Giovanni Di Giovannantonio, Sara Pietracupa, Daniela Ruggiero, Simona Scala, Stefano Gambardella, Alastair J. Noyce, Rauan Kaiyrzhanov, Ben Middlehurst, Demis A. Kia, Manuela Tan, Henry Houlden, Huw R. Morris, Helene Plun-Favreau, Peter Holmans, John Hardy, Daniah Trabzuni, John Quinn, Vivien Bubb, Kin Y. Mok, Kerri J. Kinghorn, Kimberley Billingsley, Nicholas W. Wood, Patrick Lewis, Sebastian Schreglmann, Ruth Lovering, Lea R’Bibo, Claudia Manzoni, Mie Rizig, Mina Ryten, Sebastian Guelfi, Valentina Escott-Price, Viorica Chelban, Thomas Foltynie, Nigel Williams, Karen E. Morrison, Carl Clarke, Alexis Brice, Fabrice Danjou, Suzanne Lesage, Jean-Christophe Corvol, Maria Martinez, Claudia Schulte, Kathrin Brockmann, Javier Simón-Sánchez, Peter Heutink, Patrizia Rizzu, Manu Sharma, Thomas Gasser, Mark R. Cookson, Sara Bandres-Ciga, Cornelis Blauwendraat, David W. Craig, Derek Narendra, Faraz Faghri, J. Raphael Gibbs, Dena G. Hernandez, Kendall Van Keuren-Jensen, Joshua M. Shulman, Hirotaka Iwaki, Hampton L. Leonard, Mike A. Nalls, Laurie Robak, Jose Bras, Rita Guerreiro, Steven Lubbe, Steven Finkbeiner, Niccolo E. Mencacci, Codrin Lungu, Andrew B. Singleton, Sonja W. Scholz, Xylena Reed, Roy N. Alcalay, Ziv Gan-Or, Guy A. Rouleau, Lynne Krohn, Lynne Krohn, Jacobus J. van Hilten, Johan Marinus, Astrid D. Adarmes-Gómez, Miquel Aguilar, Ignacio Alvarez, Victoria Alvarez, Francisco Javier Barrero, Jesús Alberto Bergareche Yarza, Inmaculada Bernal-Bernal, Marta Blazquez, Marta Bonilla-Toribio, Juan A. Botía, María Teresa Boungiorno, Dolores Buiza-Rueda, Fátima Carrillo, Mario Carrión-Claro, Debora Cerdan, Jordi Clarimón, Yaroslau Compta, Monica Diez-Fairen, Oriol Dols-Icardo, Jacinto Duarte, Raquel Duran, Francisco Escamilla-Sevilla, Mario Ezquerra, Cici Feliz, Manel Fernández, Rubén Fernández-Santiago, Ciara Garcia, Pedro García-Ruiz, Pilar Gómez-Garre, Maria Jose Gomez Heredia, Isabel Gonzalez-Aramburu, Ana Gorostidi Pagola, Janet Hoenicka, Jon Infante, Silvia Jesús, Adriano Jimenez-Escrig, Jaime Kulisevsky, Miguel A. Labrador-Espinosa, Jose Luis Lopez-Sendon, Adolfo López de Munain Arregui, Daniel Macias, Irene Martínez Torres, Juan Marín, Maria Jose Marti, Juan Carlos Martínez-Castrillo, Carlota Méndez-del-Barrio, Manuel Menéndez González, Marina Mata, Adolfo Mínguez, Pablo Mir, Elisabet Mondragon Rezola, Esteban Muñoz, Javier Pagonabarraga, Pau Pastor, Francisco Perez Errazquin, Teresa Periñán-Tocino, Javier Ruiz-Martínez, Clara Ruz, Antonio Sanchez Rodriguez, María Sierra, Esther Suarez-Sanmartin, Cesar Tabernero, Juan Pablo Tartari, Cristina Tejera-Parrado, Eduard Tolosa, Francesc Valldeoriola, Laura Vargas-González, Lydia Vela, Francisco Vives, Alexander Zimprich, Lasse Pihlstrom, Mathias Toft, Sulev Koks, Pille Taba, Sharon Hassin-Baer, Kari Majamaa, Ari Siitonen, Njideka U. Okubadejo, Oluwadamilola O. Ojo, Rauan Kaiyrzhanov, Chingiz Shashkin, Nazira Zharkynbekova, Vadim Akhmetzhanov, Akbota Aitkulova, Elena Zholdybayeva, Zharkyn Zharmukhanov, Gulnaz Kaishybayeva, Altynay Karimova, Dinara Sadykova, Licia Iacoviello, Fernando Gianfrancesco, Dario Acampora, Maurizio D’Esposito, Antonio Simeone, Marina Ciullo, and Teresa Esposito. Identification of sixteen novel candidate genes for late onset parkinson’s disease. Molecular Neurodegeneration, June 2021. URL: http://dx.doi.org/10.1186/s13024-021-00455-2, doi:10.1186/s13024-021-00455-2. This article has 50 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13024-021-00455-2)

[5. (Meng2020Genomic) Hui Meng, Xuewen Jiang, Jianfeng Cui, Gang Yin, Benkang Shi, Qi Liu, He Xuan, and Yu Wang. Genomic analysis reveals novel specific metastatic mutations in chinese clear cell renal cell carcinoma. BioMed Research International, 2020:1–9, September 2020. URL: http://dx.doi.org/10.1155/2020/2495157, doi:10.1155/2020/2495157. This article has 9 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2020/2495157)

[6. (Maraganore2003Case‐control) Demetrius M. Maraganore, Matthew J. Farrer, Timothy G. Lesnick, Mariza De Andrade, James H. Bower, Dena Hernandez, John A. Hardy, and Walter A. Rocca. Case‐control study of the α‐synuclein interacting protein gene and parkinson’s disease. Movement Disorders, 18(11):1233–1239, August 2003. URL: http://dx.doi.org/10.1002/mds.10547, doi:10.1002/mds.10547. This article has 12 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/mds.10547)